Vivosim Labs, INC. quarterly report, Q3 FY2014

Business context and reporting period

The filing is Organovo Holdings, Inc.’s unaudited Form 10-Q for the quarter and nine months ended December 31, 2013. The supplied metadata names Vivosim Labs, Inc., but the filing itself identifies Organovo Holdings, Inc. as the registrant. Organovo was a development-stage company developing and commercializing functional 3D human tissues for research, drug development and potential therapeutic use. It reported no product revenue in the periods presented and said it had not generated significant revenue from its planned principal operations.

Key financial metrics

Unless stated otherwise, amounts below are in millions of dollars.

At December 31, 2013, cash and cash equivalents were $49.8 million, total current assets $50.5 million, current liabilities $2.9 million and working capital $47.6 million. Total liabilities were $2.9 million, including $18,000 of capital lease obligations and a $1.0 million warrant liability. The company reported an accumulated deficit of $85.7 million.

For the nine months, operating cash use was $10.2 million, investing cash use $0.1 million and financing cash inflow $44.5 million. Cash increased by $34.2 million from March 31, 2013. No product revenue was reported; gross margin is therefore not meaningful for the period.

Material changes versus comparable periods

• Third-quarter revenue declined 67% from $349,000 to $135,000 year over year; nine-month revenue declined 73% from $1.077 million to $264,000. Management attributed the declines mainly to reduced activity under an existing collaboration and the completion of a prior agreement, partly offset by newer agreements.
• Third-quarter operating expenses rose 45% year over year to $4.8 million; nine-month expenses rose 56% to $14.2 million. Higher staffing, stock-based compensation, research activity and public-company costs contributed.
• Nine-month net loss increased from $6.5 million to $19.4 million. The comparison includes a $5.4 million non-cash expense from increased fair value of warrant liabilities in 2013; the comparable 2012 period recorded $3.6 million of warrant-related income.
• Cash increased substantially following the August 2013 public offering, which raised approximately $43.4 million net. Shares issued and outstanding increased to 77.4 million at December 31, 2013 from 64.7 million at March 31, 2013.

Outlook, commentary, risks and unusual items

• Management said available cash and expected collaboration receipts should fund operations as currently planned for at least the next 12 months. It cautioned that additional capital may be needed and may not be available on acceptable terms; a shortfall could force delays, reductions or termination of development programs.
• In November 2013, Organovo authorized an at-the-market program for up to 4 million shares; no shares had been sold under it by December 31. On January 2, 2014, it sold 280,000 shares for approximately $3.0 million net.
• The company expanded its San Diego facility from approximately 15,539 to 30,807 square feet. The amended lease carries total future minimum rental payments of $7.3 million; the expansion premises were targeted to commence in September 2014.
• Warrant-liability values rely on Level 3 assumptions and can fluctuate materially. Warrant fair-value changes affected reported earnings but are not operating cash flows.
• Organovo is defending claims by Spencer Trask concerning warrant-solicitation and placement-agency agreements. The company said the claims were without merit and had not accrued a loss because liability was not considered probable or estimable; an unfavorable outcome could materially affect liquidity or financial condition.
• The filing reported no material changes to previously disclosed risk factors, no off-balance-sheet arrangements, and effective disclosure controls. A February 2014 equity-plan amendment provides accelerated vesting for employee awards upon death or disability, subject to stated conditions.

Important facts for investors to verify

• Confirm the issuer identity: the filing is for Organovo Holdings, Inc., not Vivosim Labs, Inc.
• Track cash burn, collaboration revenue and whether management’s stated minimum 12-month funding outlook remains valid.
• Review development and commercialization progress, since revenue remained small relative to research and administrative spending.
• Assess dilution from the ATM program, outstanding warrants and equity-plan share reservations.
• Monitor the Spencer Trask dispute, expanded facility commitments and changes in the Level 3 warrant valuation.